NCT04807712 Pediatric Pertussis in Ambulatory Settings
| NCT ID | NCT04807712 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Association Clinique Thérapeutique Infantile du val de Marne |
| Condition | Pertussis/Whooping Cough |
| Study Type | OBSERVATIONAL |
| Enrollment | 898 participants |
| Start Date | 2001-05-30 |
| Primary Completion | 2030-01-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 898 participants in total. It began in 2001-05-30 with a primary completion date of 2030-01-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Since 2002, Whooping cough surveillance in pediatric private practice has been set up in France. The results of the first years, 2002-2006, have confirmed the effectiveness of the Pertussis whole-cell (Pw) vaccine and in particular the duration of protection of 9/10 years. After evaluating cases in children vaccinated with Pw vaccines, the study aims today to analyze cases in children vaccinated with Pertussis acellular (Pa) vaccines used since 2002/2003 and to assess, on an outpatient basis, the impact of new vaccine recommendations in France (in 2013, introduction of a 2 + 1 schedule - 8 weeks, 4 months and a 11-month recall - and a 6-year recall, and in 2014, update in the recommendations of exams to be prescribed based on the child's age and vaccination status).
Eligibility Criteria
Inclusion Criteria: * All children under 18 years old with a pertussis diagnosis is suspected and a biological exam is requested Exclusion Criteria: * children without symptoms with a household confirmed case * cases for which the pertussis diagnosis was not suspected by the pediatrician
Contact & Investigator
Nicole Guiso
STUDY DIRECTOR
Institut Pasteur
Frequently Asked Questions
Who can join the NCT04807712 clinical trial?
This trial is open to participants of all sexes, aged 1 Day or older, up to 18 Years, studying Pertussis/Whooping Cough. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04807712 currently recruiting?
Yes, NCT04807712 is actively recruiting participants. Contact the research team at corinne.levy@activ-france.fr for enrollment information.
Where is the NCT04807712 trial being conducted?
This trial is being conducted at Créteil, France.
Who is sponsoring the NCT04807712 clinical trial?
NCT04807712 is sponsored by Association Clinique Thérapeutique Infantile du val de Marne. The principal investigator is Nicole Guiso at Institut Pasteur. The trial plans to enroll 898 participants.